Regulatory approval
Published by the Health Canada.
Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.
This is written in the approval document as:
KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | dMMR | Colorectal Adenocarcinoma | Pembrolizumab | |
| Sensitivity (+) | MSI-H | Colorectal Adenocarcinoma | Pembrolizumab |